Virica Biotech

Virica Biotech

Biotechnology Research

Ottawa, Ontario 8,083 followers

Achieve higher yields, improve quality & scalability with Viral Sensitizers (VSE™)

About us

Cell and gene therapies, as well as viral vaccines, need higher production yields—and that's where we excel. We significantly increase yields by targeting the innate cellular defenses within production cells. These natural defenses, designed to combat foreign genetic material and inhibit viral replication, can hinder your process. Our solution is a unique panel small molecules which make up our Viral Sensitizer (VSETM) platform, which dampen cellular defenses. Using an innovative high-throughput screening process, we have developed a library of novel VSEs. Virica continues to leverage this advanced technology to pinpoint the most synergistic Viral Sensitizer molecules from our library, tailored to any virus or cell line. We customize formulations of these Viral Sensitizers to enhance virus yield in your manufacturing process or optimize the effectiveness of your viral therapies. The result is higher yields and improved quality, helping to reduce costs and improve patient access.

Industry
Biotechnology Research
Company size
11-50 employees
Headquarters
Ottawa, Ontario
Type
Privately Held
Founded
2018

Locations

Employees at Virica Biotech

Updates

Similar pages

Browse jobs

Funding